Early studies by researchers at Temple University suggest that leptin levels may respond to a leptin blocker, a promising development for a new drug to add to the arsenal for treating triple-negative breast cancer. Leptin levels are elevated in 92 percent of cases of triple-negative breast cancer and help to fuel the growth of this aggressive type of breast cancer. It is a long way from studies of mice to approval for human subjects, but these early findings show that a leptin receptor blocker extended survival significantly with very few side effects.
Let’s keep an eye on this.
Laszlo Otvos Jr., Ilona Kovalszky, Mirko Riolfi, Rita Ferla, Julia Olah, Andras Sztodola, Kaushik Nama, Annamaria Molino, Quirino Piubello, John D. Wade, Eva Surmacz. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. In press, European Journal of Cancer 2-25-115 6 7 8
© 2004-2011 Donna Peach. All rights reserved.